The current vaccine pipeline brings promise of significant global health advancements—yet development gaps remain, and the future delivery challenges must be considered.
Companies that understand the regulatory environment in Europe can keep their trials on budget and on schedule.
Navigating the challenging landscape of pharmaceutical naming—where a name must meet regulatory approval, clear trademark hurdles, and capture market attention all at once.
Coordination of KOL engagement is all but impossible if the information an organization collects about them is fragmented. What is needed is a centralized database that captures all information about an expert from the multiple touch points across functions and geographies.
As therapeutics become more personalized and targeted, technology, such as open-source software, can help companies innovate.
Identifying unique traits in patients is key to creating the most effective support programs.
Knowing that product reimbursement affects performance and varies by geography, this article proposes the use of Reimbursement Benchmark Share (RBS) to quantify the influence of reimbursement on a product’s performance.
Webinar Date/Time: Tue, Apr 23, 2024 1:00 PM EDT
What the future emergence of Amazon Pharmacy and the company’s aim to own the health experience may mean for pharma manufacturers’ engagement strategies and role in Rx delivery.
Pandemic-reinforced principles of successful drug launch.
Recent advances from COVID-19 vaccine development put pharma in place to further grow relationship with patients.
How can companies adapt their single evidence package at launch into multiple, tailored versions for HTAs that vary across different countries and regions?
How one COVID-sparked model could help usher in needed reset.
The market for prescription medicines in the United States was subject to major shifts in use across therapeutic areas in 2022, reflecting changes in patient health needs, the development, and availability of novel medicines, and complex market dynamics.
Outlining the steps to a payment approach for Medicare Part D drugs that provides savings for patients.
The pandemic has raised the stakes for companies pursuing new data-harnessing capabilities in contract management and KPI benchmarking and tracking.
Exploring practical points to further understand and strengthen quality culture.
Optimally designed SSO program can allow companies to deliver therapies to patients faster and at a more affordable cost.
Amidst lack of funding for women’s health research, industry must collaborate now to advance RMMH.
With added push from the COVID-19 pandemic, investment in promising RNA- and cell and gene therapy-based treatments and technology via industry dealmaking is growing considerably.
The right market research insights provide a richer, more-nuanced picture of your customers as people, not just as numbers on a spreadsheet.
Treating medical affairs solely as a support function is penny-wise and pound foolish. With the advent of machine learning, the medical affairs team can innovate and perform their many functions better and more efficiently.
Embracing business imperatives such as operational efficiency and a focus on a patient-centric approach can help pharma leaders provide a stable foundation amid lingering uncertainty.